Pfizer to share new data and portfolio update on Infectious disease portfolio at ICAAC meeting; invites public to view and listen to webcast of september 18 analyst meeting

NEW YORK , September 13 - Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to review key updates on infectious disease medicines and pipeline research.  The meeting will be webcast live from Chicago

Pfizer will present more than 50 abstracts on a range of new findings across bacterial, fungal and viral disease research at the ICAAC meeting. 
"Pfizer has a rich history in developing and commercializing new medicines to address infectious diseases including the recent FDA approval of HIV medication, Selzentry," said Dr. Mike Dunne, vice president, Infectious Disease Global Research and Development. "As we move into the future, our scientists will focus even more on prevention and leverage the work of other therapeutic areas, not just to treat the infections themselves, but the consequences of those infections as well."

Infectious disease represents a significant and constant threat. Today, infectious disease accounts for 21 percent of all disease-related morbidity and mortality, resulting in 12 million deaths annually.  Infectious diseases are not only spreading faster, but they appear to be emerging more quickly than ever before.  Since the 1970s, newly emerging diseases have been identified at the unprecedented rate of one or more per year.  There are now nearly 40 diseases, such as HIV and HCV, that were unknown a generation ago.  

Investor Meeting Webcast:
Pfizer Inc invites investors and the general public to listen to a webcast of a meeting with investment analysts to be held on Tuesday, September 18, at 6:00 p.m. Central Daylight Savings Time.  The analyst meeting will include presentations by Pfizer's anti-infective leadership team. 

To listen to the webcast, visit our web site at and click on the "Pfizer Anti-infective at ICAAC" link in the Investors Presentations tab on our homepage.  Information on accessing and pre-registering for the webcast will be available at beginning today.  

Visitors will be able to view and listen to an archived copy of the webcast at